HGH Fragment 176-191

HGH Fragment 176-191 is the unmodified C-terminal fragment of human growth hormone — a 16-residue peptide closed by a single disulfide bond into a cyclic loop. Ng & Bornstein (1978) provided early evidence that synthetic C-terminal hGH fragments retain metabolic activity in animal preparations, localizing functional activity to this region of the hormone. Structure–function work subsequently identified the C-terminal region spanning the published residues 177–191 as the domain associated with adipose-tissue enzyme-pathway activity, distinct from the N-terminal region that engages the growth hormone receptor and drives IGF-1 secretion. NMR structural work (Ogru et al., 2000) characterized the solution conformation of the disulfide-bonded cyclic peptide from this domain, identifying type I β-turns and describing how the Cys–Cys loop constrains the backbone. The widely used "hGH 176-191" or "Fragment 176-191" label appears throughout the secondary literature; the primary literature places the actual peptide sequence at residues 177–191. This fragment is the native parent of the later modified analog AOD-9604, which adds an N-terminal tyrosine — the present compound carries no such extension.

The unmodified C-terminal sequence has been examined directly in isolated adipose-tissue and adipocyte systems. Wu & Ng (1993) reported that synthetic hGH 177–191 displayed antilipogenic activity in rat adipose tissue comparable to that of the intact molecule, assessed by lipogenesis assays and glycerol-release measurements, and concluded that this activity resides in the C-terminal region. Wijaya & Ng (1993) examined the same antilipogenic fragment in the context of glucose transport in isolated rat adipocytes, characterizing basal and insulin-stimulated uptake. Ng et al. (2000, J Mol Endocrinol) extended this to a molecular and cellular study of a structural domain of human growth hormone in Zucker (fa/fa) rat adipose tissue, examining hormone-sensitive lipase and acetyl-CoA carboxylase activity as enzyme-level markers of pathway engagement. Together these studies characterize the unmodified fragment as an enzyme-pathway tool for examining how the C-terminal domain associates with lipid-metabolism enzymes in adipose tissue.

Several rodent studies from Ng, Heffernan, and colleagues (2000–2001) examined the C-terminal fragment and its analogs across model systems. Heffernan et al. (2000, Am J Physiol Endocrinol Metab) examined a synthetic hGH fragment (AOD-9401, somatotropin 177–191) administered orally in a genetic rodent metabolic model, with enzyme characterization in isolated human adipose tissue included as a cross-species comparator. Ng et al. (2000, Horm Res) examined Zucker (fa/fa) rats, assessing adipose enzyme activity and employing euglycemic clamp to characterize metabolic parameters and insulin action. Heffernan et al. (2001, Int J Obes) examined a rodent metabolic model by indirect calorimetry, with measurements of respiratory exchange ratio and plasma glycerol as readouts of substrate utilization. Across these studies, the unmodified domain and its close analogs served as probes for the lipid-metabolism activity attributed to the C-terminal region of growth hormone.

Heffernan et al. (2001, Endocrinology) employed beta-3 adrenergic receptor (β3-AR) knockout mice alongside wild-type and genetic metabolic-model controls to examine the signaling pathway implicated in the adipose-tissue lipid-metabolism activity studied in these models. The study measured β3-AR expression in adipose tissue and compared outcomes between knockout and intact animals over a defined study period. The design was structured to examine whether the β3-AR pathway is implicated in the adipose activity studied in these models — the work reported that the lipid-metabolism activity was not mediated directly through the β3-AR even though receptor expression changed, framing the pathway as associated rather than directly agonized.

Because HGH Fragment 176-191 corresponds to the lipolytic domain of growth hormone, the broader growth-hormone lipolysis literature provides mechanistic context for the parent activity. Dietz & Schwartz (1991) examined how growth hormone alters lipolysis and hormone-sensitive lipase activity in cultured 3T3-F442A adipocytes, characterizing a delayed, gene-expression-dependent enzyme response. Sharma et al. (2019, Am J Physiol Endocrinol Metab) examined a PPARγ–FSP27 axis in human adipocytes as a candidate mechanism for growth-hormone-associated lipolysis. Høyer et al. (2020, Physiol Rep) characterized acute growth-hormone adipose-tissue signaling across human biopsies, mice, and 3T3-L1 cells, describing suppression of antilipolytic signals. Zhao & Jiang (2023, Front Endocrinol) compared growth-hormone lipolysis across whole mice, adipose-tissue explants, and adipocyte culture, reporting a divergence between in vivo and isolated-tissue systems. Huang et al. (2023, Endocrinology) examined adipocyte subpopulations as mediators of growth-hormone-induced lipolysis and glucose tolerance in male mice. These studies define the model systems and enzyme-level readouts used to study the domain's parent activity.

Analytical-chemistry groups have characterized detection methods and metabolite profiles relevant to the C-terminal hGH fragment and its modified analog. Cox et al. (2015) developed a solid-phase-extraction assay and characterized metabolites produced in serum and urine matrices in vitro. Orlovius et al. (2013) examined immunoassay cross-reactivity in growth-hormone detection systems. Vanhee et al. (2014) reported mass-spectrometric characterization of the fragment analog in an analytical reference preparation. Review and reference literature places the fragment in a wider context: Kopchick et al. (2020) reviewed the lipolytic effects of growth hormone on adipose tissue; Vijayakumar et al. (2010) reviewed growth-hormone effects on carbohydrate and lipid metabolism; and Moré & Kenley (2014) and Stier et al. (2013) compiled nonclinical and characterization data on the Tyr-extended analog. Mendias & Awan (2026) and Liao et al. (2024) catalog the fragment within broader peptide-classification and cartilage-research reviews. These sources inform the detection, metabolite, and classification infrastructure surrounding the compound.